

Jihyun Choi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2378620/publications.pdf>

Version: 2024-02-01

16
papers

542
citations

1307594

7
h-index

1588992

8
g-index

17
all docs

17
docs citations

17
times ranked

1159
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. <i>Cancer Cell</i> , 2020, 37, 104-122.e12.	16.8	267
2	Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. <i>Cancer Research</i> , 2017, 77, 2712-2721.	0.9	110
3	Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5963-5976.	7.0	63
4	A Rad51-independent pathway promotes single-strand template repair in gene editing. <i>PLoS Genetics</i> , 2020, 16, e1008689.	3.5	33
5	Use of <i>Ex Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2393-2403.	7.0	27
6	ERK Inhibitor LY3214996-Based Treatment Strategies for <i>RAS</i> -Driven Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 641-654.	4.1	16
7	Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. <i>Molecular Oncology</i> , 2021, 15, 27-42.	4.6	15
8	Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of <i>EGFR</i> -mutant lung cancer. <i>Science Translational Medicine</i> , 2021, 13, eabb3738.	12.4	10
9	Abstract 1451: Modeling patient-derived lung cancer in mice: Preclinical tool for drug development. , 2015, , .		0
10	Abstract A105: Credentialing the concept of "eco-clinical trials": Utility of lung cancer PDX models derived from patients on AZD9291 clinical trials. , 2015, , .		0
11	Abstract 5467: Efficacy of the ERK inhibitor LY3214996 and the PI3K/mTOR inhibitor LY3023414 in patient-derived <i>RAS</i> -mutant NSCLC models. , 2018, , .		0
12	Abstract 955: Combined inhibition of MEK and mTOR pathways is effective in <i>NRAS</i> Q61K mutant small cell lung cancer. , 2018, , .		0
13	A Rad51-independent pathway promotes single-strand template repair in gene editing. , 2020, 16, e1008689.		0
14	A Rad51-independent pathway promotes single-strand template repair in gene editing. , 2020, 16, e1008689.		0
15	A Rad51-independent pathway promotes single-strand template repair in gene editing. , 2020, 16, e1008689.		0
16	A Rad51-independent pathway promotes single-strand template repair in gene editing. , 2020, 16, e1008689.		0